The PennZone

PITTSBURGH, Oct. 24, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) will announce financial results for the third quarter of 2022 on Monday, November 7, 2022. Executive Chairman Robert J. Coury, Chief Executive Officer Michael Goettler, President Rajiv Malik, and Chief Financial Officer Sanjeev Narula will host a webcast at 8:30 a.m. ET on the same date to review the quarterly results and provide an update on the company's February 28 Investor Event.

More on The PennZone

• Summer Festivals in Gunma Prefecture: Song, Dance, and Vibrant Color – Get There Via Tobu Railway!
• Jetperch Introduces Joulescope JS320 Precision Energy Analyzer for Low-Power Embedded System Development
• AI-Powered Trading Bots Are Transforming Forex, Gold, and Digital Markets as DefiHash Expands Intelligent Quantitative Infrastructure
• Early Bird Registration Open for FLYING HY, the Top Hydrogen and Battery Electric Aviation Event
• Eichelberger Performing Arts Center Welcomes New Executive Director

Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 800.225.9448 or 203.518.9708 for international callers (Conference ID: VTRSQ322).  A replay of the webcast also will be available on the website.

About Viatris
Viatris Inc. (NASDAQ: VTRS) is a global healthcare company empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway®. Formed in November 2020, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical, and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris' portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, a portfolio of biosimilars and a variety of over-the-counter consumer products. With approximately 37,000 colleagues globally, Viatris is headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on Twitter at @ViatrisInc, LinkedIn and YouTube.

More on The PennZone

• Century Fasteners Corp. Hires Tony Marano as Director of Human Resources
• Accelerating Toward Commercialization as FDA Momentum, AI Neurotherapy & Manufacturing Expansion Drive Multi-Catalyst Growth Story; N A S D A Q: NRXP
• New Wisconsin Report Shows Most Plane Crashes Happen Outside Major Hubs
• Thou Shalt not Commit Adultery Lifetime Movie Discussion
• Book Florida Keys Accommodations Early with KeysCaribbean and Save 15 Percent

SOURCE Viatris Inc.

---

Show All News | Disclaimer | Report Violation